What a management disaster this was, from start to finish. Absolutely amazing that this couldn’t be pulled off in a metro of 7.5 million and with all that Texas money. My thoughts are with the journalists, who did far better work than their bosses. houstonlanding.org/houston-landin…

This is awful, infuriating -- and bad for Houston and Houstonians. It is also *NOT* the fault of the Landing's many dedicated journalists. The Landing's CEO and board could not have run the newsroom into the ground quicker if they'd tried (see: texasmonthly.com/news-politics/…).

sending love to the journalists at the houston landing. the Houston Landing NewsGuild fought to have a thriving newsroom where they could do important work. the landing closing is a loss for the whole community. houston badly needs more accountability and this certainly won't help.

Startup Glycomine raises $115M to push rare disease drug deeper into testing biopharmadive.com/news/glycomine… by Gwendolyn Wu

Bluebird says Ayrmid missed deadline for rival takeover bid biopharmadive.com/news/bluebird-… $BLUE by Gwendolyn Wu

Texas Medical Center through the years ⁦Houston Chronicle⁩ houstonchronicle.com/projects/timel…

being a reporter is just solving harder and harder problems until you get laid off or die (you probably won't retire)

Siren, a gene therapy startup, tests unconventional alternative to venture funding biopharmadive.com/news/siren-bio… by Gwendolyn Wu

The team at Siren Biotechnology, Inc. is trying a Silicon Valley method for investment: crowdfunding. "The scientist in me is just like, 'We’re going to run this experiment and see if it works,'" Dr. Nicole Paulk told BioPharma Dive biopharmadive.com/news/siren-bio…

Novo to work with Septerna in hunt for oral obesity drugs biopharmadive.com/news/novo-nord… $NVO $SEPN by Gwendolyn Wu

Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot biopharmadive.com/news/prime-med… $PRME by Gwendolyn Wu

Cancer drugmaker iTeos to shut down biopharmadive.com/news/iteos-ope… by Gwendolyn Wu $ITOS $THRD $CRGX $KROS

Sage, following Setbacks, to sell to Supernus for $561M biopharmadive.com/news/sage-ther… $SAGE $SUPN by Delilah Alvarado

A longer ‘winter’: Public funding slowdown heightens pressure on #biotech #startups biopharmadive.com/news/biotech-s… by Gwendolyn Wu

well, that was certainly a jolt in the east bay #earthquake

Bristol Myers shuffles its executive ranks with new CMO biopharmadive.com/news/bristol-m… by Gwendolyn Wu $BMY $AZN

Congratulations to the CSPA Workshop Class of 2025! The graduates from our 74th summer high school journalism workshop gave us a lot of optimism for the future of journalism. Thank you to our all-volunteer staff who made our 74th a huge success. Bring on No. 75!

Xoma strikes deals to buy struggling biotechs HilleVax, Lava biopharmadive.com/news/xoma-hill… by Gwendolyn Wu #biotech $XOMA $HLVX $LAVA

New: Increased attention on Texas House Democratic leader Rep. Gene Wu of Houston comes with more anti-Asian insults. texastribune.org/2025/08/06/tex…

Strand raises another $153M to make ‘programmable’ mRNA drugs biopharmadive.com/news/strand-se… by Gwendolyn Wu #biotech #startups